2003
No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention
Resnic F, Wainstein M, Lee M, Behrendt D, Wainstein R, Ohno-Machado L, Kirshenbaum J, Rogers C, Popma J, Piana R. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. American Heart Journal 2003, 145: 42-46. PMID: 12514653, DOI: 10.1067/mhj.2003.36.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionPostprocedural myocardial infarctionStrong independent predictorMyocardial infarctionIndependent predictorsSodium nitroprussideInhospital outcomesCoronary interventionClinical outcomesSaphenous vein graft interventionIntracoronary vasodilator therapyVein graft interventionAdministration of verapamilAcute myocardial infarctionRate of deathInhospital mortalityVasodilator therapyCardiogenic shockBaseline demographicsGraft interventionUnstable anginaAdverse eventsConsecutive patientsIntracoronary verapamilInfarction
2001
Vascular closure devices and the risk of vascular complications after percutaneous coronary intervention in patients receiving glycoprotein IIb-IIIa inhibitors
Resnic F, Blake G, Ohno-Machado L, Selwyn A, Popma J, Rogers C. Vascular closure devices and the risk of vascular complications after percutaneous coronary intervention in patients receiving glycoprotein IIb-IIIa inhibitors. The American Journal Of Cardiology 2001, 88: 493-496. PMID: 11524056, DOI: 10.1016/s0002-9149(01)01725-8.Peer-Reviewed Original ResearchMeSH KeywordsAge DistributionAgedAnalysis of VarianceAneurysm, FalseAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedArteriovenous FistulaChi-Square DistributionCoronary DiseaseCoronary Vessel AnomaliesCoronary VesselsEquipment SafetyFemaleHematomaHumansIncidenceMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionProbabilityRetrospective StudiesRisk AssessmentRisk FactorsSex DistributionConceptsPercutaneous coronary interventionVascular closure deviceGlycoprotein IIb-IIIa antagonistsVascular complication ratesVascular complicationsClosure deviceCoronary interventionComplication rateLower vascular complication ratesOverall vascular complication rateGlycoprotein IIb-IIIa inhibitorsIIb-IIIa inhibitorsSubgroup of patientsLength of stayHospital stayConsecutive patientsLarge hematomaSurgical repairArteriovenous fistulaPatient populationUnivariate analysisRetrospective analysisComplicationsPatient comfortPatients